单次鼻内美布福替宁治疗难治性抑郁症的随机临床试验
这项2b期随机双盲试验在澳大利亚、欧洲和美国的38个中心纳入193例难治性抑郁症成人患者,比较单次鼻内美布福替宁苯甲酸盐8 mg、12 mg与0.3 mg低剂量对照的疗效与安全性。8 mg组同样显著优于对照,且多数受试者给药后2小时内达到出院准备标准。
要点
- 单次鼻内美布福替宁8 mg或12 mg均在第29天显著改善难治性抑郁症MADRS评分。
- 第29天缓解率8 mg组26%、12 mg组18%、0.3 mg组8%,应答率分别为35%、34%、12%。
- 多数受试者给药后2小时内可出院,8 mg组85%、12 mg组78%,监测时间较短。
核心结论
- 单次鼻内美布福替宁苯甲酸盐耐受性良好,可快速、显著且持久地减轻难治性抑郁症症状。
- 该给药方式可能缩短监测时间并减少门诊就诊,相比裸盖菇素和艾司氯胺酮有望改善治疗可及性。
研究设计与样本
- 2b期随机双盲试验,8周盲法随访,2023年9月至2025年4月在澳大利亚、欧洲和美国的38个中心开展。
- 纳入193例18至75岁、当前发作对2至5种抗抑郁药无效的中重度抑郁症成人,随机接受单次鼻内美布福替宁苯甲酸盐8 mg(n=46)、12 mg(n=73)或0.3 mg低剂量对照(n=74),并辅以心理支持。
主要发现
- 8 mg和12 mg组在给药后2至57天所有其他时间点的MADRS降幅相似且显著大于0.3 mg组。
- 第29天应答率:8 mg组35%、12 mg组34%、0.3 mg组12%;缓解率:8 mg组26%、12 mg组18%、0.3 mg组8%。
- 治疗中出现的不良事件发生率:8 mg组76%、12 mg组85%、0.3 mg组73%,其中99.7%为轻或中度。
关键数值与推荐
- 主要终点为12 mg组与0.3 mg组基线至第29天MADRS总分变化,MADRS评分范围0-60分,分数越高抑郁越重。
- 给药后90分钟开始评估出院准备情况,8 mg组85%、12 mg组78%的受试者在给药后2小时内达到出院准备标准。
临床怎么用
- 对于当前发作对2至5种抗抑郁药无效的中重度抑郁症成人,单次鼻内美布福替宁8 mg或12 mg可作为快速起效的潜在治疗选择。
- 给药后需进行约2小时的临床监测,多数受试者在此时间内达到出院准备标准,可能减少门诊停留和就诊次数。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Psychedelics represent a potential breakthrough for treatment-resistant depression; however, the prolonged in-clinic monitoring required for compounds such as psilocybin and lysergic acid diethylamide is a logistical hurdle to widespread use. Intranasal mebufotenin (5-methoxy-N,N-dimethyltryptamine), a 5-hydroxytryptamine 1A (5-HT1A) and 5-HT2A agonist associated with brief psychedelic experiences, may address this limitation. OBJECTIVE: To evaluate the safety, efficacy, and time to discharge readiness following a single dose of intranasal mebufotenin benzoate in adults with treatment-resistant depression. DESIGN, SETTING, AND PARTICIPANTS: Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up conducted between September 2023 and April 2025 at 38 sites in Australia, Europe, and the US. Participants were aged 18 to 75 years with moderate to severe major depressive disorder nonresponsive to 2 to 5 antidepressant trials in the current episode. The last date of follow-up was April 28, 2025. INTERVENTIONS: After antidepressant washout as needed, participants were randomly assigned to receive a single dose of intranasal mebufotenin benzoate, 8 mg (n = 46), 12 mg (n = 73), or 0.3 mg (a low-dose comparator; n = 74), alongside psychological support. MAIN OUTCOMES AND MEASURES: The primary end point was total score change on the Montgomery-Åsberg Depression Rating Scale (MADRS; score range, 0-60; higher scores indicate more severe depression) from baseline to day 29 in the 12-mg vs 0.3-mg dose groups. Eighteen secondary end points were assessed for the 12-mg and 8-mg vs 0.3-mg doses. Discharge readiness was assessed starting 90 minutes after dosing. RESULTS: Among the 193 included participants, the mean age was 41 (SD, 11.1) years and 59.1% were female. From baseline to day 29, treatment with 12-mg intranasal mebufotenin benzoate vs the 0.3-mg dose (the primary end point) was associated with significantly reduced MADRS scores (mean score change, -11.1 [SD, 11.6] vs -5.5 [SD, 9.9], respectively; mean difference, -5.3 [95% CI, -8.9 to -1.8]; P = .003). The 8-mg dose also led to reduced scores from baseline to day 29 (mean score change, -12.5 [SD, 12.7]) vs the 0.3-mg dose (mean difference, -6.2 [95% CI, -10.2 to -2.1]; P = .003). MADRS reductions with the 8-mg and 12-mg doses were similar and significantly greater at all other time points from 2 to 57 days post dose vs the 0.3-mg dose. Day 29 response rates were 35%, 34%, and 12% and remission rates were 26%, 18%, and 8% in the 8-mg, 12-mg, and 0.3-mg dose groups, respectively. Treatment-emergent adverse events were reported in 76%, 85%, and 73% of participants in the 8-mg, 12-mg, and 0.3-mg dose groups, respectively; most events (99.7%) were mild or moderate. Overall, most participants were deemed ready for discharge within 2 hours post dose (85% for 8 mg and 78% for 12 mg). CONCLUSIONS AND RELEVANCE: In adults with treatment-resistant depression, single doses of intranasal mebufotenin benzoate were well tolerated and produced rapid, robust, and durable reductions in depressive symptoms. Intranasal mebufotenin benzoate may improve treatment access and convenience, requiring a shorter monitoring period and fewer clinic visits compared with psilocybin and esketamine, respectively. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05870540.
引用
- Feifel D, Seynaeve M, Cubala WJ, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. 2026. PMID: 42931733. doi:10.1001/jama.2026.18380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。